Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
Published Online: 11 FEB 2014
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Zhang J, Xiao Y, Meng L, Yang X, Shi S. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010968. DOI: 10.1002/14651858.CD010968.
- Publication Status: New
- Published Online: 11 FEB 2014
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of patients with relapsing-remitting multiple sclerosis to prevent disease activity.